Abstract
This study evaluated the effect of switching outpatients with schizophrenia and antipsychotic-induced sexual dysfunction to open-label quetiapine treatment. Secondary objectives were to compare the antipsychotic and prolactin-related effects of quetiapine versus prestudy antipsychotic treatment. Eight patients with at least moderately severe antipsychotic-induced sexual dysfunction (N = 7 taking risperidone, 4-6 mg/d; N = 1 taking haloperidol, 10 mg/d) were evaluated prospectively after they switched to 6 weeks of quetiapine treatment. The assessments that we used included evaluations of sexual functioning (Arizona Sexual Experience Scale [ASEX]; McGahuey et al., 2000), psychopathology (Positive and Negative Syndrome Scale [PANSS]; Kay, Fiszbeinm, & Opler, 1997), adverse events, and plasma prolactin levels. Quetiapine was associated with clinically and statistically significant improvement in ASEX total scores (p = 0.008) and significantly decreased PANSS total scores (p = 0.03). Plasma prolactin levels tended to decrease after the transition to quetiapine (p = 0.09). Quetiapine appears to offer an option to reduce antipsychotic-induced sexual dysfunction for outpatients with schizophrenia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 325-332 |
| Number of pages | 8 |
| Journal | Journal of Sex and Marital Therapy |
| Volume | 30 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 2004 |
Fingerprint
ASJC Scopus subject areas
- Social Sciences (miscellaneous)
- Psychology(all)
- Clinical Psychology
Cite this
An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. / Byerly, Matthew J.; Lescouflair, Emmeline; Weber, Mary T.; Bugno, Rhiannon M.; Fisher, Robert; Carmody, Thomas; Varghese, Femina; Rush, A. John.
In: Journal of Sex and Marital Therapy, Vol. 30, No. 5, 10.2004, p. 325-332.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction
AU - Byerly, Matthew J.
AU - Lescouflair, Emmeline
AU - Weber, Mary T.
AU - Bugno, Rhiannon M.
AU - Fisher, Robert
AU - Carmody, Thomas
AU - Varghese, Femina
AU - Rush, A. John
PY - 2004/10
Y1 - 2004/10
N2 - This study evaluated the effect of switching outpatients with schizophrenia and antipsychotic-induced sexual dysfunction to open-label quetiapine treatment. Secondary objectives were to compare the antipsychotic and prolactin-related effects of quetiapine versus prestudy antipsychotic treatment. Eight patients with at least moderately severe antipsychotic-induced sexual dysfunction (N = 7 taking risperidone, 4-6 mg/d; N = 1 taking haloperidol, 10 mg/d) were evaluated prospectively after they switched to 6 weeks of quetiapine treatment. The assessments that we used included evaluations of sexual functioning (Arizona Sexual Experience Scale [ASEX]; McGahuey et al., 2000), psychopathology (Positive and Negative Syndrome Scale [PANSS]; Kay, Fiszbeinm, & Opler, 1997), adverse events, and plasma prolactin levels. Quetiapine was associated with clinically and statistically significant improvement in ASEX total scores (p = 0.008) and significantly decreased PANSS total scores (p = 0.03). Plasma prolactin levels tended to decrease after the transition to quetiapine (p = 0.09). Quetiapine appears to offer an option to reduce antipsychotic-induced sexual dysfunction for outpatients with schizophrenia.
AB - This study evaluated the effect of switching outpatients with schizophrenia and antipsychotic-induced sexual dysfunction to open-label quetiapine treatment. Secondary objectives were to compare the antipsychotic and prolactin-related effects of quetiapine versus prestudy antipsychotic treatment. Eight patients with at least moderately severe antipsychotic-induced sexual dysfunction (N = 7 taking risperidone, 4-6 mg/d; N = 1 taking haloperidol, 10 mg/d) were evaluated prospectively after they switched to 6 weeks of quetiapine treatment. The assessments that we used included evaluations of sexual functioning (Arizona Sexual Experience Scale [ASEX]; McGahuey et al., 2000), psychopathology (Positive and Negative Syndrome Scale [PANSS]; Kay, Fiszbeinm, & Opler, 1997), adverse events, and plasma prolactin levels. Quetiapine was associated with clinically and statistically significant improvement in ASEX total scores (p = 0.008) and significantly decreased PANSS total scores (p = 0.03). Plasma prolactin levels tended to decrease after the transition to quetiapine (p = 0.09). Quetiapine appears to offer an option to reduce antipsychotic-induced sexual dysfunction for outpatients with schizophrenia.
UR - http://www.scopus.com/inward/record.url?scp=4644344336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4644344336&partnerID=8YFLogxK
U2 - 10.1080/00926230490465082
DO - 10.1080/00926230490465082
M3 - Article
C2 - 15672600
AN - SCOPUS:4644344336
VL - 30
SP - 325
EP - 332
JO - Journal of Sex and Marital Therapy
JF - Journal of Sex and Marital Therapy
SN - 0092-623X
IS - 5
ER -